Key result
GLP-1 receptor agonists result in ~20% less total weight loss than metabolic and bariatric surgery.
Why the study?
GLP-1 receptor agonists have seen sharply rising use for obesity, but no studies incorporated the latest evidence directly comparing their effectiveness and costs against metabolic and bariatric surgery.
Do GLP-1 receptor agonists improve percentage of total weight loss compared to metabolic and bariatric surgery in patients undergoing obesity management?
Meta-Analysis (n=14,548)
Do GLP-1 receptor agonists improve percentage of total weight loss compared to metabolic and bariatric surgery in patients undergoing obesity management?
Metabolic and bariatric surgery achieves greater and more sustained weight loss, superior BMI reduction, and better glycemic control than GLP-1 receptor agonists, with lower out-of-pocket costs at 24 months.
Answers are grounded in this paper and cite their sources.
Surgery yields greater weight loss than GLP-1 RAs; confirms bariatric procedures as superior for durable obesity management.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have seen a sharp rise in use for obesity management in recent years. No studies incorporate the latest evidence directing comparing their effectiveness and costs against metabolic and bariatric surgery (MBS). Methods: We performed a systematic review on five different databases. The primary outcome was the difference in percentage of total weight loss (%TWL). Secondary outcomes included differences in glycated hemoglobin (HbA1c), body mass index (BMI), and cots out-of-pockets (OOP) from patients. The random-effects model was used to calculate the pooled odds ratios (OR) and mean difference (MD) with 95% confidence intervals (CI). Results: Of 1763 studies screened, 11 were included, comprising 14,548. The GLP-1 group accounted for 51.1% of patients ( n = 7435). There was no significant difference in age or sex distribution between groups. Baseline BMI was lower in GLP-1 RA patients (MD = −1.23; P = .002). GLP-1 RA had a lower %TWL (MD = −19.98; P < .001) and BMI reduction (MD = −7.17; P < .001). Lower %TWL was persistent from 12 months (MD = −23.69) to 24 months (MD = −19.57). Reduction in HbA1c was also lower in GLP-1 RA (MD = −0.99; P < .001), with a similar trend in subgroup of liraglutide 1.2 mg daily versus Roux-en-Y gastric bypass (MD = −1.62). Mean OOP cost at 24 months was significantly higher in the GLP-1 group (MD = +$749.38; P < .001). Conclusion: MBS achieves greater and more sustained weight loss, superior BMI reduction, and better glycemic control than GLP-1 agonists, while also being associated with lower 24-month OOP costs. GLP-1 therapies do not match the effectiveness of surgery, yet they may serve as a complementary strategy in multidisciplinary obesity management.
No takes yet. Share an insight, caveat, or question.
Rivero-Moreno et al. (2026) conducted a meta-analysis in Obesity (n=14,548). GLP-1 receptor agonists vs. Metabolic and bariatric surgery (MBS) was evaluated on Percentage of total weight loss (%TWL) (MD -19.98, p=<0.001). GLP-1 receptor agonists resulted in a lower percentage of total weight loss compared to metabolic and bariatric surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: